药品注册申请号:021285
申请类型:NDA (新药申请)
申请人:NOVARTIS
申请人全名:NOVARTIS PHARMACEUTICALS CORP
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 TRILEPTAL OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Yes Yes AB 2001/05/25 2001/05/25 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2019/01/04 SUPPL-36(补充) Approval Labeling STANDARD
2018/03/22 SUPPL-35(补充) Approval Labeling STANDARD
2017/11/17 SUPPL-34(补充) Approval Labeling STANDARD
2017/03/23 SUPPL-31(补充) Approval Labeling STANDARD
2014/07/03 SUPPL-27(补充) Approval Labeling UNKNOWN
2014/06/06 SUPPL-30(补充) Approval Labeling STANDARD
2014/05/08 SUPPL-29(补充) Approval Manufacturing (CMC) STANDARD
2014/02/28 SUPPL-28(补充) Approval Manufacturing (CMC) STANDARD
2013/02/08 SUPPL-23(补充) Approval Labeling STANDARD
2011/10/30 SUPPL-25(补充) Approval REMS N/A
2011/03/03 SUPPL-22(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-20(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-19(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-18(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-15(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-13(补充) Approval Labeling STANDARD
2011/03/03 SUPPL-9(补充) Approval Labeling STANDARD
2009/04/23 SUPPL-21(补充) Approval Labeling 901 REQUIRED
2007/08/31 SUPPL-14(补充) Approval Labeling STANDARD
2005/10/28 SUPPL-8(补充) Approval Efficacy PRIORITY
2005/03/25 SUPPL-7(补充) Approval Labeling STANDARD
2002/09/10 SUPPL-3(补充) Approval Manufacturing (CMC) STANDARD
2002/04/01 SUPPL-2(补充) Approval Labeling STANDARD
2002/01/18 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
2001/05/25 ORIG-1(原始申请) Approval Type 3 - New Dosage Form STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
001 7037525 2018/02/12 U-724 PDF格式**本条是由Drugfuture回溯的历史信息**
7037525*PED 2018/08/12 PDF格式**本条是由Drugfuture回溯的历史信息**
8119148 2020/12/19 Y U-724 PDF格式**本条是由Drugfuture回溯的历史信息**
8119148*PED 2021/06/19 PDF格式**本条是由Drugfuture回溯的历史信息**
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
001 I-478 2008/10/28**本条是由Drugfuture回溯的历史信息**
PED 2009/04/28**本条是由Drugfuture回溯的历史信息**
与本品治疗等效的药品
活性成分:OXCARBAZEPINE 剂型/给药途径:SUSPENSION;ORAL 规格:300MG/5ML 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
021285 001 NDA TRILEPTAL OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription Yes Yes AB 2001/05/25 NOVARTIS
078734 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2009/06/26 SUN PHARM INDS LTD
202961 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2012/09/17 AMNEAL PHARMS
201193 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Discontinued No No AB 2012/10/03 HIKMA
212428 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2021/06/21 CHARTWELL RX
211420 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Discontinued No No AB 2021/07/09 RENEW PHARMS
215726 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2022/08/30 RUBICON
209652 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2022/11/04 BIONPHARMA
215332 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2022/11/30 AUCTA
213183 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2023/03/18 ALKEM LABS LTD
216749 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2023/10/20 HETERO LABS LTD III
217782 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2024/02/14 MEDLEY PHARMS
218278 001 ANDA OXCARBAZEPINE OXCARBAZEPINE SUSPENSION;ORAL 300MG/5ML Prescription No No AB 2024/03/01 BIOCON PHARMA
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database